PROCEPT BioRobotics (PRCT) Stock Forecast, Price Target & Predictions
PRCT Stock Forecast
PROCEPT BioRobotics stock forecast is as follows: an average price target of $73.00 (represents a -10.00% downside from PRCT’s last price of $81.11) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
PRCT Price Target
The average price target for PROCEPT BioRobotics (PRCT) is $73.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $95.00 to $49.00. This represents a potential -10.00% downside from PRCT's last price of $81.11.
PRCT Analyst Ratings
According to 2 Wall Street analysts, PROCEPT BioRobotics's rating consensus is 'Buy'. The analyst rating breakdown for PRCT stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
PROCEPT BioRobotics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 03, 2024 | Richard Newitter | Truist Financial | $95.00 | $79.00 | 20.25% | 17.12% |
| Jul 16, 2024 | Richard Newitter | Truist Financial | $79.00 | $68.90 | 14.66% | -2.60% |
| May 06, 2024 | Matt O'Brien | Piper Sandler | $75.00 | $64.31 | 16.62% | -7.53% |
| May 02, 2024 | Richard Newitter | Truist Financial | $72.00 | $60.61 | 18.79% | -11.23% |
| Sep 02, 2022 | Nathan Treybeck | Wells Fargo | $49.00 | $40.38 | 21.35% | -39.59% |
The latest PROCEPT BioRobotics stock forecast, released on Sep 03, 2024 by Richard Newitter from Truist Financial, set a price target of $95.00, which represents a 20.25% increase from the stock price at the time of the forecast ($79.00), and a 17.12% increase from PRCT last price ($81.11).
PROCEPT BioRobotics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 4 |
| Avg Price Target | $95.00 | $87.00 | $80.25 |
| Last Closing Price | $81.11 | $81.11 | $81.11 |
| Upside/Downside | 17.12% | 7.26% | -1.06% |
In the current month, the average price target of PROCEPT BioRobotics stock is $95.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 17.12% increase as opposed to PROCEPT BioRobotics's last price of $81.11. This month's average price target is up 9.20% compared to last quarter, and up 18.38% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 02, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 06, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 06, 2024 | Piper Sandler | Overweight | Overweight | Hold |
PROCEPT BioRobotics's last stock rating was published by Cowen & Co. on Jul 02, 2024. The company gave PRCT a "Buy" rating, the same as its previous rate.
PROCEPT BioRobotics Financial Forecast
PROCEPT BioRobotics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $35.10M | $33.10M | $24.40M | $23.78M | $20.35M | $16.69M | $14.20M | $12.92M | $8.67M |
| Avg Forecast | $118.10M | $104.60M | $95.70M | $91.50M | $87.76M | $76.08M | $73.46M | $65.56M | $66.01M | $53.31M | $50.10M | $41.58M | $41.79M | $34.09M | $30.31M | $24.36M | $22.91M | $17.04M | $14.41M | $12.11M | $8.95M | $7.11M |
| High Forecast | $120.59M | $106.80M | $97.72M | $93.43M | $89.61M | $77.69M | $75.01M | $66.94M | $67.40M | $54.33M | $51.15M | $42.46M | $42.67M | $34.81M | $30.95M | $24.87M | $23.40M | $17.40M | $14.74M | $12.39M | $9.16M | $7.27M |
| Low Forecast | $114.59M | $101.49M | $92.86M | $88.78M | $85.15M | $73.82M | $71.28M | $63.61M | $64.05M | $52.35M | $48.61M | $40.35M | $40.54M | $33.08M | $29.41M | $23.63M | $22.23M | $16.54M | $14.04M | $11.80M | $8.73M | $6.93M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.09% | 1.00% | 1.04% | 1.19% | 1.16% | 1.17% | 1.44% | 1.22% |
PROCEPT BioRobotics's average Quarter revenue forecast for Dec 23 based on 5 analysts is $41.79M, with a low forecast of $40.54M, and a high forecast of $42.67M. PRCT's average Quarter revenue forecast represents a 19.04% increase compared to the company's last Quarter revenue of $35.10M (Sep 23).
PROCEPT BioRobotics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-25.61M | $-24.32M | $-27.60M | $-24.05M | $-20.45M | $-17.03M | $-14.97M | $-40.59M | $-11.84M |
| Avg Forecast | $-112.75M | $-99.86M | $-91.37M | $-87.36M | $-83.79M | $-72.64M | $-70.13M | $-62.59M | $-63.02M | $-50.89M | $-47.83M | $-39.70M | $-39.89M | $-32.55M | $-28.94M | $-23.26M | $-21.88M | $-13.55M | $-13.75M | $-17.56M | $-8.55M | $-10.71M |
| High Forecast | $-109.40M | $-96.90M | $-88.65M | $-84.76M | $-81.30M | $-70.48M | $-68.05M | $-60.73M | $-61.15M | $-49.98M | $-46.41M | $-38.52M | $-38.71M | $-31.58M | $-28.08M | $-22.56M | $-21.23M | $-10.84M | $-13.40M | $-14.05M | $-8.33M | $-8.57M |
| Low Forecast | $-115.13M | $-101.97M | $-93.29M | $-89.20M | $-85.55M | $-74.17M | $-71.61M | $-63.91M | $-64.35M | $-51.87M | $-48.84M | $-40.53M | $-40.73M | $-33.24M | $-29.55M | $-23.75M | $-22.34M | $-16.26M | $-14.07M | $-21.07M | $-8.75M | $-12.85M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.79% | 0.84% | 1.19% | 1.10% | 1.51% | 1.24% | 0.85% | 4.75% | 1.11% |
undefined analysts predict PRCT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than PROCEPT BioRobotics's previous annual EBITDA (undefined) of $NaN.
PROCEPT BioRobotics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-24.62M | $-25.29M | $-27.70M | $-31.30M | $-23.12M | $-20.49M | $-18.67M | $-25.08M | $-14.10M |
| Avg Forecast | $-16.00M | $-17.04M | $-17.04M | $-18.58M | $-13.16M | $-18.50M | $-20.24M | $-21.89M | $-20.24M | $-25.34M | $-26.98M | $-28.66M | $-22.63M | $-27.13M | $-29.45M | $-30.03M | $-28.10M | $-16.14M | $-24.88M | $-20.11M | $-20.13M | $-12.76M |
| High Forecast | $-15.38M | $-16.38M | $-16.38M | $-17.87M | $-12.65M | $-17.78M | $-19.46M | $-21.05M | $-19.46M | $-23.22M | $-25.94M | $-27.56M | $-20.57M | $-26.08M | $-28.32M | $-28.87M | $-27.01M | $-12.91M | $-24.06M | $-16.09M | $-19.47M | $-10.21M |
| Low Forecast | $-16.44M | $-17.50M | $-17.50M | $-19.09M | $-13.52M | $-19.00M | $-20.80M | $-22.49M | $-20.80M | $-26.92M | $-27.72M | $-29.45M | $-25.71M | $-27.87M | $-30.26M | $-30.85M | $-28.87M | $-19.37M | $-25.63M | $-24.13M | $-20.73M | $-15.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 0.86% | 0.92% | 1.11% | 1.43% | 0.82% | 0.93% | 1.25% | 1.11% |
PROCEPT BioRobotics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PRCT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
PROCEPT BioRobotics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $32.88M | $32.44M | $30.13M | $26.03M | $24.75M | $19.66M | $18.39M | $31.86M | $12.12M |
| Avg Forecast | $287.64M | $254.76M | $233.08M | $222.85M | $213.75M | $185.30M | $178.91M | $159.67M | $160.77M | $129.83M | $122.02M | $101.27M | $101.77M | $83.04M | $73.83M | $59.33M | $55.80M | $13.87M | $35.09M | $29.49M | $21.81M | $17.32M |
| High Forecast | $293.70M | $260.12M | $237.99M | $227.55M | $218.25M | $189.21M | $182.68M | $163.03M | $164.15M | $132.32M | $124.59M | $103.41M | $103.92M | $84.79M | $75.38M | $60.58M | $56.98M | $16.64M | $35.89M | $30.17M | $22.31M | $17.72M |
| Low Forecast | $279.09M | $247.19M | $226.16M | $216.23M | $207.40M | $179.80M | $173.60M | $154.92M | $155.99M | $127.49M | $118.39M | $98.26M | $98.75M | $80.57M | $71.64M | $57.56M | $54.15M | $11.10M | $34.20M | $28.74M | $21.26M | $16.88M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.40% | 0.44% | 0.51% | 0.47% | 1.78% | 0.56% | 0.62% | 1.46% | 0.70% |
PROCEPT BioRobotics's average Quarter SG&A projection for Dec 23 is $101.77M, based on 5 Wall Street analysts, with a range of $98.75M to $103.92M. The forecast indicates a 209.50% rise compared to PRCT last annual SG&A of $32.88M (Sep 23).
PROCEPT BioRobotics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.56 | $-0.61 | $-0.70 | $-0.52 | $-0.46 | $-0.43 | $-0.58 | $-1.22 |
| Avg Forecast | $-0.31 | $-0.33 | $-0.33 | $-0.36 | $-0.25 | $-0.36 | $-0.39 | $-0.42 | $-0.39 | $-0.49 | $-0.52 | $-0.56 | $-0.44 | $-0.53 | $-0.57 | $-0.58 | $-0.54 | $-0.48 | $-0.48 | $-0.47 | $-0.39 | $-0.41 |
| High Forecast | $-0.30 | $-0.32 | $-0.32 | $-0.35 | $-0.25 | $-0.34 | $-0.38 | $-0.41 | $-0.38 | $-0.45 | $-0.50 | $-0.53 | $-0.40 | $-0.51 | $-0.55 | $-0.56 | $-0.52 | $-0.46 | $-0.47 | $-0.46 | $-0.38 | $-0.40 |
| Low Forecast | $-0.32 | $-0.34 | $-0.34 | $-0.37 | $-0.26 | $-0.37 | $-0.40 | $-0.44 | $-0.40 | $-0.52 | $-0.54 | $-0.57 | $-0.50 | $-0.54 | $-0.59 | $-0.60 | $-0.56 | $-0.49 | $-0.50 | $-0.49 | $-0.40 | $-0.42 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | 1.05% | 1.29% | 1.08% | 0.95% | 0.91% | 1.49% | 2.98% |
According to undefined Wall Street analysts, PROCEPT BioRobotics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PRCT previous annual EPS of $NaN (undefined).
PROCEPT BioRobotics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| OFIX | Orthofix Medical | $16.76 | $31.00 | 84.96% | - |
| ESTA | Establishment Labs | $44.20 | $78.00 | 76.47% | Buy |
| NPCE | NeuroPace | $7.43 | $12.88 | 73.35% | Buy |
| FNA | Paragon 28 | $7.39 | $11.50 | 55.62% | Buy |
| SGHT | Sight Sciences | $6.95 | $10.33 | 48.63% | Hold |
| LUNG | Pulmonx | $8.31 | $12.25 | 47.41% | Buy |
| LIVN | LivaNova | $48.53 | $71.25 | 46.82% | Buy |
| CNMD | CONMED | $75.40 | $101.00 | 33.95% | Buy |
| SIBN | SI-BONE | $15.73 | $20.00 | 27.15% | Buy |
| KIDS | OrthoPediatrics | $32.28 | $40.80 | 26.39% | Buy |
| RXST | RxSight | $54.96 | $68.60 | 24.82% | Buy |
| ITGR | Integer | $126.78 | $131.00 | 3.33% | Buy |
| SRDX | Surmodics | $39.36 | $39.50 | 0.36% | Buy |
| PRCT | PROCEPT BioRobotics | $81.11 | $73.00 | -10.00% | Buy |
PRCT Forecast FAQ
Is PROCEPT BioRobotics a good buy?
Yes, according to 2 Wall Street analysts, PROCEPT BioRobotics (PRCT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of PRCT's total ratings.
What is PRCT's price target?
PROCEPT BioRobotics (PRCT) average price target is $73 with a range of $49 to $95, implying a -10.00% from its last price of $81.11. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will PROCEPT BioRobotics stock go up soon?
According to Wall Street analysts' prediction for PRCT stock, the company can go down by -10.00% (from the last price of $81.11 to the average price target of $73), up by 17.12% based on the highest stock price target, and down by -39.59% based on the lowest stock price target.
Can PROCEPT BioRobotics stock reach $120?
PRCT's average twelve months analyst stock price target of $73 does not support the claim that PROCEPT BioRobotics can reach $120 in the near future.
What is PROCEPT BioRobotics's current price target trend?
1 Wall Street analyst forecast a $95 price target for PROCEPT BioRobotics (PRCT) this month, up 17.12% from its last price of $81.11. Compared to the last 3 and 12 months, the average price target increased by 7.26% and decreased by -1.06%, respectively.
What are PROCEPT BioRobotics's analysts' financial forecasts?
PROCEPT BioRobotics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $302.86M (high $309.24M, low $293.86M), average EBITDA is $-289M (high $-281M, low $-295M), average net income is $-73.793M (high $-70.942M, low $-75.813M), average SG&A $737.63M (high $753.17M, low $715.72M), and average EPS is $-1.429 (high $-1.374, low $-1.469). PRCT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $409.9M (high $418.53M, low $397.72M), average EBITDA is $-391M (high $-380M, low $-400M), average net income is $-68.657M (high $-66.005M, low $-70.537M), average SG&A $998.33M (high $1.02B, low $968.67M), and average EPS is $-1.33 (high $-1.279, low $-1.366).
Did the PRCT's actual financial results beat the analysts' financial forecasts?
Based on PROCEPT BioRobotics's last annual report (Dec 2023), the company's revenue was $136.19M, beating the average analysts forecast of $130.55M by 4.32%. Apple's EBITDA was $-109M, missing the average prediction of $-125M by -12.41%. The company's net income was $-106M, missing the average estimation of $-109M by -3.06%. Apple's SG&A was $131.77M, missing the average forecast of $317.97M by -58.56%. Lastly, the company's EPS was $0, missing the average prediction of $-2.116 by -100.00%. In terms of the last quarterly report (Sep 2023), PROCEPT BioRobotics's revenue was $35.1M, beating the average analysts' forecast of $34.09M by 2.96%. The company's EBITDA was $-25.609M, missing the average prediction of $-32.551M by -21.33%. PROCEPT BioRobotics's net income was $-24.622M, missing the average estimation of $-27.128M by -9.24%. The company's SG&A was $32.88M, missing the average forecast of $83.04M by -60.40%. Lastly, the company's EPS was $0, missing the average prediction of $-0.526 by -100.00%